Soliman GA, et al. (2010) mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 285, 7866-79 20022946

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T37-p - 4E-BP1 (human) ▲

Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes rapamycin no change compared to control Torin1 decrease

T46-p - 4E-BP1 (human) ▲

Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes rapamycin no change compared to control Torin1 decrease

S473-p - Akt1 (human) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase rapamycin insulin no effect upon treatment-induced increase wortmannin insulin inhibit treatment-induced increase serum increase EGF no change compared to control phorbol_ester no change compared to control

T183-p - AMPKA1 (human) ▲

Modsite: sDGEFLRtsCGsPNy SwissProt Entrez-Gene Orthologous residues AMPKA1 (human): T183‑p, AMPKA1 iso2 (human): T198‑p, AMPKA1 (mouse): T183‑p, AMPKA1 (rat): T183‑p, AMPKA1 (fruit fly): T184‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes 2-deoxyglucose increase

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin no change compared to control serum increase EGF increase phorbol_ester increase

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin no change compared to control serum increase EGF increase phorbol_ester increase

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin no change compared to control serum increase EGF increase phorbol_ester increase

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin no change compared to control serum increase EGF increase phorbol_ester increase

S2481-p - mTOR (human) ▲

Modsite: tVPEsIHsFIGDGLV SwissProt Entrez-Gene Orthologous residues mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE mTOR (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE mTOR (human) pharmacological activator of upstream enzyme, transfection of wild-type enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody, activation of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase rapamycin insulin inhibit treatment-induced increase mTORC1-associated; no rapamycin effect on mTORC2-associated mTOR wortmannin insulin inhibit treatment-induced increase Torin1 decrease rapamycin Torin1 no effect upon treatment-induced increase mTORC2, IP Rictor rapamycin no change compared to control whole cell lysates (WCL) Torin1 no change compared to control whole cell lysates serum increase serum_withdrawal decrease amino_acids increase IP Raptor amino_acids no change compared to control WCL amino_acid_starvation decrease IP Raptor amino_acid_starvation no change compared to control WCL 2-deoxyglucose decrease IP Raptor and WCL EGF increase phorbol_ester increase Raptor (human) no change compared to control RHEB (human) Raptor (human) increase insulin Raptor (human) increase rapamycin Raptor (human), RHEB (human) inhibit treatment-induced increase mTOR (human) Raptor (human), RHEB (human) inhibit treatment-induced increase mTor kinase-dead Downstream Regulation Effect of modification (function):  enzymatic activity, induced

T412-p - p70S6K (human) ▲

Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene Orthologous residues p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase wortmannin insulin inhibit treatment-induced increase rapamycin insulin inhibit treatment-induced increase 2-deoxyglucose decrease serum increase phorbol_ester increase mTOR (human), Raptor (human) increase slight increase RHEB (human) mTOR (human), Raptor (human) augment treatment-induced increase insulin mTOR (human), Raptor (human) augment treatment-induced increase rapamycin mTOR (human), Raptor (human), RHEB (human) inhibit treatment-induced increase RHEB (human) mTOR (human), Raptor (human) decrease Kinase dead mTOR

T36-p - 4E-BP1 (mouse) ▲

Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes rapamycin decrease Torin1 decrease

T45-p - 4E-BP1 (mouse) ▲

Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene Orthologous residues 4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes rapamycin decrease Torin1 decrease

S473-p - Akt1 (mouse) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase rapamycin insulin no effect upon treatment-induced increase wortmannin insulin inhibit treatment-induced increase TSC1 (mouse) no change compared to control insulin TSC1 (mouse) no change compared to control rapamycin insulin TSC1 (mouse) no change compared to control wortmannin insulin TSC1 (mouse) no change compared to control

S2481-p - mTOR (mouse) ▲

Modsite: tVPEsIHsFIGDGLV SwissProt Entrez-Gene Orthologous residues mTOR (human): S2481‑p, mTOR (mouse): S2481‑p, mTOR (rat): S2481‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE mTOR (mouse) genetic knockout/knockin of upstream enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, activation of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase rapamycin insulin inhibit treatment-induced increase mTORC1-associated mTOR; no rapamycin effect in mTORC2-associated mTOR wortmannin insulin inhibit treatment-induced increase mTORC1 and mTORC2 associated rapamycin decrease Torin1 decrease amino_acids increase insulin amino_acids augment treatment-induced increase rapamycin amino_acids, insulin inhibit treatment-induced increase wortmannin amino_acids, insulin inhibit treatment-induced increase amino_acid_starvation decrease 2-deoxyglucose no change compared to control TSC1 (mouse) decrease hamartin -/- increases insulin TSC1 (mouse) increase rapamycin insulin TSC1 (mouse) inhibit treatment-induced increase wortmannin insulin TSC1 (mouse) inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  enzymatic activity, induced

T412-p - p70S6K (mouse) ▲

Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene Orthologous residues p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  3T3-L1 (fibroblast), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes insulin increase rapamycin insulin inhibit treatment-induced increase amino_acids, insulin increase rapamycin amino_acids, insulin inhibit treatment-induced increase wortmannin amino_acids, insulin inhibit treatment-induced increase amino_acid_starvation decrease 2-deoxyglucose decrease TSC1 (mouse) decrease hamartin -/- increase insulin increase insulin TSC1 (mouse) increase rapamycin insulin TSC1 (mouse) inhibit treatment-induced increase wortmannin insulin TSC1 (mouse) inhibit treatment-induced increase